HMGB1 and glaucoma: The latest research has also found that intravitreal injection of anti-High Mobility Group Box 1 (HMGB1) monoclonal antibody can effectively regulate inflammatory responses in animal models of glaucoma, providing a theoretical basis for the development of sustained-release preparations targeting neuroinflammation (Tonner et al., 2022).